ClinicalTrials.gg
CompletedNCT03386825COLONGUpdated May 15, 2018

Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib

An observational study in Colorectal Neoplasms, sponsored by Bayer. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-15.

Sponsored by Bayer · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
76
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Colorectal Neoplasms by Bayer — 2 open to participants now, 2 under way, none of them phase 3. Colorectal Neoplasms · Bayer.

Enrollment
15th of 16
76 · median 651
Started
2018
with 2 others
Observational
16 of 32
none open now
Registered
18th of 32
by date

Among the 32 studies in Colorectal Neoplasms by Bayer, this one is the 15th largest by enrollment of the 16 observational ones that give a count, is one of 3 that started in 2018, is one of 16 observational ones, and was the 18th registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

2 of the 32 studies in Colorectal Neoplasms by Bayer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Colorectal Neoplasms by Bayer, or all of them as a file.
02

Study summary

The aim of this local NIS(Non-Interventional Study) is to determine the proportion of Belgian patients with a duration of treatment(DoT) to Stivarga of 4 months or more in relation to the total population of Belgian metastatic colorectal cancer(mCRC) patients who were treated with Stivarga between the 1st of July 2015 and 31 July 2017. In addition, this study aims to describe the clinical characteristics of Belgian patients with a short- or long-term DoT to Stivarga.

03

Conditions studied

  • Colorectal Neoplasms

Keywords

  • Metastatic Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Belgian mCRC patients who were treated with Stivarga between the 1st of July 2015 and 31 July 2017.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients ≥ 18 years of age.
  • Patients who suffer from mCRC and who started treatment with Stivarga between the 1st of July 2015 and 31 July 2017.
  • Patients who already received alternative treatment options before Stivarga for the treatment of mCRC or who were not eligible for other treatment options.
  • performance status (ECOG PS) ≤ 1 at start of Stivarga treatment.
  • Sufficient kidney, liver and bone marrow function start of Stivarga treatment.
  • ≥ 3 months at start of Stivarga treatment

Exclusion criteria

Exclusion Criteria:

  • Patients participating in an program/clinical trial with interventions outside of routine clinical practice during the observational period.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
76 participants (actual)
Patient registry
No

Groups and cohorts

  • Regorafenib_DoT<4 months

    DoT \< 4 months

    Drug: Regorafenib (Stivarga, BAY73-4506)

  • Regorafenib_4 months ≤ DoT < 12 months

    4 months ≤ DoT \< 12 months

    Drug: Regorafenib (Stivarga, BAY73-4506)

  • Regorafenib_DoT ≥ 12 months

    DoT ≥ 12 months

    Drug: Regorafenib (Stivarga, BAY73-4506)

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of patients with a DoT to Stivarga of more than 4 months versus total study sample

    Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017

  2. ECOG performance status (0, 1)

    ECOG: Eastern Cooperative Oncology Group

    Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017

  3. Primary site of disease

    Rectum, Left-sided colon, Right-sided colon, Colon and rectum, Transverse, Unknown (in colon)

    Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017

  4. Tumor resection (yes, no, unknown)

    Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017

  5. Specific site of metastasis

    Lung, Liver, Bone, Extraregional nodes, Peritoneum, Multiple, Unknown

    Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017

  6. KRAS mutation (yes, no, unknown)

    Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017

  7. RAS mutation (yes, no, unknown)

    Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017

  8. BRAF mutation (yes, no, unknown)

    Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017

Secondary outcomes

  1. Start date of Stivarga treatment

    Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017

  2. Number of prior treatment lines for metastatic cancer larger than 3 (yes, no, unknown)

    Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017

  3. Reason for discontinuation of Stivarga treatment

    progression - symptomatic, Progression - radiological, Progression - radiological + symptomatic, Progression - unknown, Intolerability, Death, other, unknown, not applicable

    Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017

  4. Subsequent mCRC treatment

    Chemotherapy IV, Chemotherapy oral, Biologic therapy, Chemotherapy + biologic therapy, BSC, Other, Unknown, Not applicable

    Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017

  5. Last daily Stivarga dose

    80 mg, 120 mg, 160 mg, other, unknown

    Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017

  6. Duration of treatment (months)

    Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017

07

Study locations

1 site
  • Belgium
    Multiple Locations, Belgium
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in May 2018, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2017
First posted
Dec 29, 2017
StartActual
Jan 31, 2018
Primary completionActual
May 1, 2018
CompletionActual
May 1, 2018
Last update
May 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03386825
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Dec 29, 2017
Start date
Jan 31, 2018
Primary completion
May 1, 2018
Completion
May 1, 2018
Last update
May 15, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion